IP Library › Granted Patent US 10,154,951
Granted Patent B2
US 10,154,951 · App. 15/244,587 · Granted Dec 18, 2018

Cross linked silk-hyaluronic acid composition

Inventors: Elizabeta Pavlovic (Santa Barbara, CA); Monica A. Serban (Melrose, MA); Xiaojie Yu (Irvine, CA); Nicholas J. Manesis (Escondido, CA)
Assignee: ALLERGAN, INC.
A61K8/64A61K8/735A61L27/20A61L27/227A61L27/3604A61L27/52A61Q19/08C08B37/0072C08H1/00C08J3/075C08J3/246C08L5/08C08L89/00A61L2400/06A61L2430/04A61L2430/34C08J2305/08C08J2489/00C08J2489/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,154,951
App. No.
15/244,587
Granted
Dec 18, 2018
Kind
B2
Abstract

Compositions useful as dermal fillers and methods using such compositions to treat various skin and soft tissue conditions. The dermal fillers can comprise silk attached to hyaluronic acid using for example two cross linkers and can be used to treat of facial imperfections, facial defects, facial augmentations, breast imperfections, breast augmentations or breast reconstructions.

Claims (10)

1. A process for making an injectable composition for treating a soft tissue condition, the process comprising:

(a) activating a hyaluronic acid using a carbodiimide coupling agent, and

(b) cross linking the activated hyaluronic acid to silk using a multiamine cross linker whereby the silk is crosslinked to the hyaluronic acid via amide bonding to the multiamine cross linker.

2. The process of claim 1 , wherein the multiamine cross linker is (i) 3-[3-(3-amino propoxy)-2,2-bis(3-amino-propoxymethyl)-propoxy]propylamine (4AA) or (ii) a diamine cross linker.

3. The process of claim 2 , wherein the diamine cross linker is a linear diamine cross linker selected from the group consisting of a hexamethylene diamine (HMDA), lysine, lysine methyl ester, and lysine ethyl ester.

4. The process of claim 1 , wherein the carbodiimide coupling agent is a water soluble carbodiimide.

5. The process of claim 4 , wherein the water soluble carbodiimide coupling agent is 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide (EDC).

6. The process of claim 1 , further comprising using an activating agent in conjunction with the carbodiimide coupling agent.

7. The process of claim 6 , wherein the activating agent is a water soluble activating agent.

8. The process of claim 7 , wherein the water soluble activating agent is a N-hydroxysuccinimide (NHS) or a N-hydroxysulfosuccinimide (sulfoNHS).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2016
From: PAVLOVIC, ELIZABETA; SERBAN, MONICA A.; YU, XIAOJIE; MANESIS, NICHOLAS J.
To: ALLERGAN, INC.
Reel/Frame 039511/0048 →
Continuity (2)
Continuation 13868010 · Apr 22, 2013
Related Publication 20160361247A1 · Dec 15, 2016
Cited By (2)
US 12,296,067 US 12,611,484